Lurbinectedin
High Grade Neuroendocrine Cancers
Jazz PharmaceuticalsSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
49 Active assets in the High Grade Neuroendocrine Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | B |
Everolimus AIO-Studien-gGmbH | Phase 2 | B |
Carboplatin Phanes Therapeutics | Phase 2 | B |
Pembrolizumab Ochsner Health System | Phase 2 | B |
View all 50 →
Same molecule, other indications
Lurbinectedin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →